U.S. Markets close in 2 hrs 55 mins
  • S&P 500

    4,158.72
    -26.75 (-0.64%)
     
  • Dow 30

    34,030.66
    -170.01 (-0.50%)
     
  • Nasdaq

    13,880.83
    -171.51 (-1.22%)
     
  • Russell 2000

    2,220.41
    -42.26 (-1.87%)
     
  • Crude Oil

    63.36
    +0.23 (+0.36%)
     
  • Gold

    1,771.80
    -8.40 (-0.47%)
     
  • Silver

    25.79
    -0.31 (-1.21%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.5178%)
     
  • 10-Yr Bond

    1.5910
    +0.0180 (+1.14%)
     
  • Vix

    18.37
    +2.12 (+13.05%)
     
  • GBP/USD

    1.3988
    +0.0148 (+1.0729%)
     
  • USD/JPY

    108.0590
    -0.7240 (-0.6655%)
     
  • BTC-USD

    54,711.77
    -929.27 (-1.67%)
     
  • CMC Crypto 200

    1,229.63
    -69.32 (-5.34%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Can You Imagine How Jubilant Champions Oncology's (NASDAQ:CSBR) Shareholders Feel About Its 220% Share Price Gain?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stock. For instance, the price of Champions Oncology, Inc. (NASDAQ:CSBR) stock is up an impressive 220% over the last five years. Also pleasing for shareholders was the 29% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 19% in 90 days).

See our latest analysis for Champions Oncology

Because Champions Oncology made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 5 years Champions Oncology saw its revenue grow at 25% per year. Even measured against other revenue-focussed companies, that's a good result. So it's not entirely surprising that the share price reflected this performance by increasing at a rate of 26% per year, in that time. This suggests the market has well and truly recognized the progress the business has made. To our minds that makes Champions Oncology worth investigating - it may have its best days ahead.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's good to see that Champions Oncology has rewarded shareholders with a total shareholder return of 39% in the last twelve months. That gain is better than the annual TSR over five years, which is 26%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for Champions Oncology that you should be aware of before investing here.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.